Genmab’s Rybrevant challenge is rendered moot

Any difficulties Genmab might have faced surrounding its work on a molecule with mechanistic similarity to Rybrevant have just been averted. That’s because development of this project, GEN1286, appears to have been discontinued, with its sole clinical study ceasing recruitment after enrolling just 23 of a planned 260 solid tumour patients. The move emerged in an update on GEN1286’s clinicaltrials.gov entry, which Genmab has confirmed to ApexOnco accurately reflects the project’s status. Rybrevant and GEN1286 both hit EGFR and cMet, the former as a naked antibody and the latter with an ADC modality. GEN1286 came from Genmab's $1.8bn takeover of ProfoundBio, and it was unclear whether Genmab’s separate interest in Rybrevant, a drug that arose from a long-standing discovery alliance with Johnson & Johnson, might have precluded the Danish firm from working on competing projects hitting the same targets. Genmab must have decided that it could proceed, starting a phase 1/2 solid tumour study of GEN1286 in November 2024. GEN1286’s sidelining follows recent discontinuations of GEN1160 and GEN1107, and means that the only ProfoundBio asset still in active development is rinatabart sesutecan, an anti-FRα ADC in phase 3 that has been challenged by Lilly’s LY4170156.

What’s left of ProfoundBio?

Source: OncologyPipeline.